FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,396 | -59.1% | 50,187 | -8.1% | 0.00% | -66.7% |
| Q2 2023 | $259,948 | +86839.1% | 54,611 | +4.2% | 0.00% | -40.0% |
| Q1 2023 | $299 | -43.9% | 52,434 | -0.7% | 0.01% | -54.5% |
| Q4 2022 | $533 | -99.9% | 52,784 | +12.3% | 0.01% | -52.2% |
| Q3 2022 | $1,053,000 | +15.7% | 46,999 | +28.0% | 0.02% | -4.2% |
| Q2 2022 | $910,000 | +55.3% | 36,715 | +142.9% | 0.02% | +71.4% |
| Q1 2022 | $586,000 | -70.1% | 15,114 | -54.9% | 0.01% | -57.6% |
| Q4 2021 | $1,961,000 | +567.0% | 33,515 | +841.4% | 0.03% | +450.0% |
| Q1 2021 | $294,000 | -82.5% | 3,560 | -91.5% | 0.01% | -91.8% |
| Q3 2020 | $1,680,000 | +29.8% | 42,035 | +11.5% | 0.07% | +14.1% |
| Q2 2020 | $1,294,000 | +79.2% | 37,710 | -18.9% | 0.06% | +156.0% |
| Q3 2019 | $722,000 | – | 46,484 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |